Canada Recommends Public Coverage for Second Alzheimer’s Drug
Canada’s Drug Agency is recommending public coverage for donanemab, a disease-modifying treatment for early-stage Alzheimer’s disease, though the expert committee set strict pricing and clinical conditions before provincial drug plans should pay the estimated $47,250 annual cost. According to a draft report released by the Canadian Drug Expert Committee, the infusion therapy provides clinical benefits … Read more